Home Uncategorized

Uncategorized

Latest

Dr. Harpreet Singh Discusses the Conduct of FDA Clinical Trials During the COVID-19 Pandemic

lungcanc

Lung Cancer Surgery in the COVID-19 Era: What Has Changed?

TERAVOLT: Increased Risk of Morbidity for Patients with Lung Cancer and COVID-19 Drives Research Collaboration

On the Backs of Specialists: LDCT Screening Has Heightened the Importance of Recent Improvements in Surgical and Radiation Techniques

‘Never Too Late’: Tobacco Cessation Programs Benefit Patients With Cancer

Stage IIIA NSCLC: A Review of Recent and Ongoing Trials Trial

lungcanc

Oncology Trials Could Benefit From Increased Data on Tobacco Use

lungcanc

Insight Into Genomic Correlates of PD-L1 Expression and the Response to...

lungcanc

TERAVOLT: Global Registry Investigates Outcomes Among Patients With Thoracic Cancer and...

lungcanc

Lung Cancer Considered – Episode XXV – Mar 16, 2020 Dr....

lungcanc

Grappling with Coronavirus (SARS-CoV-2)

lungcanc

IASLC’s Guide to COVID-19 and Lung Cancer

lungcanc

c-MET Antibody–Drug Conjugates: Misconceptions Corrected, Excitement Explained— An Interview with Dr....

lungcanc

The IASLC Fight Against Lung Cancer in Peru and Latin America

lungcanc

Pasi A. Janne, MD, PhD

lungcanc

12 Page 1 of 2

Meeting News

Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation

Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation

TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse

cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib